Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

81. Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis

Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva [Adalimumab, etanercept (...) A, Ciapponi A, Mengarelli C. Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva. [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 294. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related issues on the use

Health Technology Assessment (HTA) Database.2014

82. Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents ? second line

Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents ? second line Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line NIHR HSC Citation NIHR HSC. Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review

Health Technology Assessment (HTA) Database.2014

83. Adalimumab

Adalimumab USE OF ADALIMUMAB IN PREGNANCY 0344 892 0909 USE OF ADALIMUMAB IN PREGNANCY (Date of issue: May 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Adalimumab is a human monoclonal antibody administered in the treatment (...) of rheumatoid arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriasis, Crohn’s disease, and ulcerative colitis. Its use in these conditions is reserved for patients where other systemic therapies are ineffective or unsuitable. There are very limited data specific to adalimumab use during pregnancy. Studies investigating the use of anti-TNFα therapies during pregnancy show no compelling evidence

UK Teratology Information Service2014

84. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2013. 2013 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies. Final publication URL Indexing Status Subject indexing assigned

Health Technology Assessment (HTA) Database.2013

85. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial 23962455 2013 12 05 2014 02 11 2016 12 15 1468-2060 73 1 2014 Jan Annals of the rheumatic diseases Ann. Rheum. Dis. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. 86-94 10.1136/annrheumdis-2013-203843 To compare over 2 years the safety, efficacy (...) and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients with rheumatoid arthritis (RA). AMPLE is a phase IIIb, 2-year, randomised, investigator-blinded study with a 1-year primary endpoint. Biologic-naive patients with active RA and an inadequate response to MTX were randomised to 125 mg abatacept weekly or 40 mg adalimumab bi-weekly, both with a stable dose of MTX. Of 646 patients randomised, 79.2% abatacept and 74.7% adalimumab patients

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

86. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. BACKGROUND: Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients (...) with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy. METHODS: This trial was done at 161 sites worldwide. Patients with early (<1 year duration) rheumatoid arthritis naive to methotrexate were randomly allocated (by interactive voice response system, in a 1:1 ratio, block size four) to adalimumab (40 mg every other week) plus methotrexate (initiated at 7·5 mg/week, increased by 2·5 mg every 1-2 weeks to a maximum

Lancet2013

87. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2113. 2013 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis, in children aged 2 to 4 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate

Health Technology Assessment (HTA) Database.2013

88. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No.1513. 2013 Authors' conclusions Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to non steroidal anti-inflammatory drugs (NSAIDs). Final publication URL Indexing Status

Health Technology Assessment (HTA) Database.2013

89. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial

Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial 23897775 2014 10 31 2014 12 30 2015 11 19 1468-2060 73 12 2014 Dec Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. 2074-81 10.1136/annrheumdis-2013-203586 To evaluate the effect of adding a 10-week treatment of adalimumab to a standardised treatment (...) with corticosteroids on the ability to taper more rapidly corticosteroid doses in patients with newly diagnosed giant cell arteritis (GCA). Patients included in this double-blind, multicentre controlled trial were randomly assigned to receive a 10-week subcutaneous treatment of adalimumab 40 mg every other week or placebo in addition to a standard prednisone regimen (starting dose 0.7 mg/kg per day). The primary endpoint was the percentage of patients in remission on less than 0.1 mg/kg of prednisone at week 26

EvidenceUpdates2013

90. Humira (Adalimumab, Abbott Laboratories) for treatment of pediatric crohn's disease

Humira (Adalimumab, Abbott Laboratories) for treatment of pediatric crohn's disease Humira (Adalimumab; Abbott Laboratories) for treatment of pediatric crohn's disease Humira (Adalimumab; Abbott Laboratories) for treatment of pediatric crohn's disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab; Abbott Laboratories) for treatment

Health Technology Assessment (HTA) Database.2013

92. Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis

Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1977 Publication date: 15/08/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 19/06/2013 AWMSG meeting date: 17 (...) /07/2013 Submission Type: Limited Submission Status: Superseded Advice No: 2113 Ministerial ratification: 14/08/2013 Current Progress Submission received NMG meeting AWMSG meeting Ministerial Ratification AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended as an option for use within NHS

All Wales Medicines Strategy Group2013

94. Adalimumab (Humira) - ankylosing spondylitis

Adalimumab (Humira) - ankylosing spondylitis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1381 Publication date: 31/07/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 15/05/2013 AWMSG meeting date: 12/06/2013 Submission Type: Full Submission Status: Superseded Advice No: 1513 (...) Ministerial ratification: 29/07/2013 Current Progress Submission received NMG meeting AWMSG meeting Ministerial Ratification AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without radiographic evidence

All Wales Medicines Strategy Group2013

95. Adalimumab (Humira) - for the treatment of severe active Crohn's disease in paediatric patients

Adalimumab (Humira) - for the treatment of severe active Crohn's disease in paediatric patients Published 08 July 2013 Product Update: adalimumab 40mg solution for injection in a single-use pre-filled syringe, pre- filled pen and a 40mg/0.8mL paediatric vial (Humira®) (No: 880/13) AbbVie Ltd 07 June 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira®) is accepted for restricted use within NHS Scotland. Indication under review: is indicated for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies. SMC

Scottish Medicines Consortium2013

96. Adalimumab (Humira) - in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis

Adalimumab (Humira) - in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis Published 08 July 2013 Product Update: adalimumab 40mg solution for injection in pre-filled syringe or pen, 40mg/0.8ml solution for injection vial for paediatric use (Humira®) (No:881/13) AbbVie Ltd 07 June 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira®) solution for injection is accepted for restricted use within NHS Scotland. Indication under review: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be

Scottish Medicines Consortium2013

98. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind,

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, 23434570 2014 02 28 2014 04 29 2015 11 19 1468-2060 73 4 2014 Apr Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid (...) arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. 654-61 10.1136/annrheumdis-2012-202735 An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency

EvidenceUpdates2013

99. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab (...) mg per kg bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks or adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks for 24 weeks. Investigators, patients, and sponsor personnel were masked to assignment. The primary endpoint was change in disease activity score using 28 joints (DAS28) from baseline to week 24. This trial is registered with ClinicalTrials.gov, number NCT01119859 . FINDINGS: We screened 452 patients and enrolled 326

Lancet2013

100. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study 23316080 2014 02 05 2014 04 28 2016 12 15 1468-2060 73 3 2014 Mar Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. 536-43 10.1136/annrheumdis-2012 (...) -202433 To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics. This randomised, double-blind, placebo-controlled, multicentre study evaluated adalimumab 40 mg every other week+MTX 6-8 mg every week versus MTX 6-8 mg every week alone for 26 weeks in patients with RA (≤2-year duration). The primary endpoint was inhibition of radiographic progression (change (Δ) from baseline

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro